Provided by Tiger Fintech (Singapore) Pte. Ltd.

Galmed Pharmaceuticals

2.51
+0.01000.40%
Post-market: 2.40-0.1100-4.38%16:12 EDT
Volume:688.02K
Turnover:1.61M
Market Cap:4.16M
PE:-0.22
High:2.54
Open:2.49
Low:2.15
Close:2.50
Loading ...

Company Profile

Company Name:
Galmed Pharmaceuticals
Exchange:
NASDAQ
Establishment Date:
2000
Employees:
6
Office Location:
16 Abba Hillel Road,Ramat Gan,Israel
Zip Code:
5250608
Fax:
- -
Introduction:
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company develops MyBiotics which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.

Directors

Name
Position
Allen Baharaff
President and Chief Executive Officer,Director
David Sidransky
Lead Independent Director
Carol L. Brosgart
Director
Marshall A. Heinberg
Director
Ran Oren
Director
Shmuel Nir
Director
Tali Yaron Eldar
Director
William S. Marth
Director

Shareholders

Name
Position
Allen Baharaff
President and Chief Executive Officer,Director
Guy Nehemya
Chief Operating Officer
Yohai Stenzler
Chief Financial Officer
Liat Hayardeny
Chief Scientist Officer
Tali Gorfine
Chief Medical Officer